Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.

Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis

“…Fortunately, GI adverse effects are usually transient and improve with time, occurring mainly in the initiation and dose escalation periods [20]. This can be managed by initiating at a lower dose, followed by slow dose escalation and using antiemetics when required [20, 83].…”

Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials

“…Nevertheless, the elevated incidence of adverse events and the propensity for treatment discontinuation necessitate a careful evaluation in light of its favorable profile. Literature reports indicate that GLP-RAs are linked with adverse effects, notably during dose escalation [ 21 ]. Analyses such as this raise intriguing new therapeutic opportunities, such as a synergistic strategy involving co-administration of once-weekly insulin in order to minimize the need for higher Dulaglutide doses, maximize efficacy and safety, and thereby improve adherence and tolerability of the medication [ 22 ].…”

Semaglutide-Induced Lupus Erythematosus With Multiorgan Involvement

“…Semaglutide is an analog of native GLP-1 RA with slight modifications, has recently gained approval, and is renowned for its effectiveness and favorable safety profile [ 10 ]. Given its recent introduction to the market, specific reports of autoimmune reactions and related side effects have not been extensively studied yet [ 11 , 12 ]. However, in recent post-marketing surveillance based on reports from individuals who experienced side effects while using Ozempic, SLE-like symptoms were reported by seven out of 12,332 individuals (0.06%).…”